6 November 2017

Africa: Overlooked Infection Kills 150,000 Babies a Year, Mostly in Africa - Study

Dakar — Nearly one in five pregnant women worldwide is infected with Group B Streptococcus

A bacterial infection passed from mothers to babies kills around 150,000 unborn children and infants a year but has been widely overlooked in developing countries, researchers said on Monday as they urged faster progress on developing a vaccine.

Nearly one in five pregnant women worldwide is infected with Group B Streptococcus (GBS), which causes stillbirths, deaths and permanent problems such as vision and hearing loss in babies, researchers found in the first global study of the disease.

Africa is disproportionately affected, with 65 percent of the world's stillbirths and infant deaths from GBS, though it is home to only about 13 percent of the world's population, according to the study led by the London School of Hygiene and Tropical Medicine.

Most of these deaths could be prevented by a new vaccine that is still in clinical development, the study found.

"The burden of Group B strep has been underappreciated, particularly in low and middle-income countries," co-author Shabir Madhi of Wits University in South Africa told the Thomson Reuters Foundation.

In high-income countries pregnant women are typically screened for GBS and given antibiotics during labour to prevent infecting the baby, which is effective, the researchers said.

But this is rarely done in developing countries where laboratory screening is limited and many births take place at home, they said.

In Africa the rate of infection in pregnant women is also higher than worldwide, ranging from 25 to 35 percent, although it is not clear why, said Madhi.

There is no vaccine currently available to prevent GBS, but one still undergoing trials was found to be 80 percent effective and could potentially prevent 231,000 infant and maternal GBS cases a year, the study found.

"If the vaccine is developed, the place it's most needed is in Africa," Madhi said. Unfortunately, he added, it will likely not be on the market for at least five years.

"It is now essential to accelerate the GBS vaccine development activities," said co-author Johan Vekemans of the World Health Organisation in a statement.

Reporting By Nellie Peyton; Editing by Ros Russell

Our Standards: The Thomson Reuters Trust Principles.

Africa

Mogae Chairs African of the Year Prize Committee

A former President of Botswana, Festus G. Mogae has formally assumed the Chair of the Prize Committee for African of the… Read more »

Copyright © 2017 Thomson Reuters Foundation. All rights reserved. Distributed by AllAfrica Global Media (allAfrica.com). To contact the copyright holder directly for corrections — or for permission to republish or make other authorized use of this material, click here.

AllAfrica publishes around 900 reports a day from more than 140 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.